H. Lundbeck A/S
The answer first
Does H. Lundbeck beat the market?
Yes, H. Lundbeck has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 98% of Nordic stocks
- Quality91
- Value56
- Trend98
No. 1 of 195 in healthcare
Expectations in the price
Low expectations
For the share to return about 9% a year from today's price, it is enough that the cash H. Lundbeck keeps stays flat for 10 years.
Max for seven days
Follow H. Lundbeck with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about H. Lundbeck
Your first answer is free, no account needed.
Do you own H. Lundbeck, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with H. Lundbeck and a few more. Free, no card.
Super Stock+44.6%In short
- H. Lundbeck has risen 88.8% over the past year, including dividends.
- Overall, H. Lundbeck ranks better than 98% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 42.0%. The price is at its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 98% of Nordic stocks.
No. 1 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 32 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.31
- Asset turnoverSales divided by everything the company owns0.48
- Return on equityProfit divided by equity+14.3%
- Cash conversionOperating cash flow divided by profit1.32
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 36 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.1
- P/SPrice divided by sales2.2
- P/EPrice divided by earnings14.3
- P/CFPrice divided by operating cash flow10.8
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 8 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+49.1%
- 6 months+69.2%
- 9 months+72.9%
- 12 months+88.8%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own H. Lundbeck
6 funds we follow own H. Lundbeck. The share is how much of the fund the stock makes up.
- Norway1
- Sweden1
- Denmark4
From the funds' latest known holdings.
About H. Lundbeck
H. Lundbeck A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 5,000 employees.
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression.


See the full analysis of H. Lundbeck.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card